health

Longevity medicine's do-or-die moment

If cell reprogramming is successful, it'll be a watershed moment in the study of aging.

Longevity medicine's do-or-die moment

TL;DR

  • The first human trial of a cellular reprogramming drug, intended to make cells younger, has commenced.
  • This early-stage clinical trial aims to assess the safety of performing cellular reprogramming in humans.
  • The therapy targets three genes to partially reprogram old cells, with the initial application being for eye disorders like glaucoma.
  • The company sponsoring the trial, Life Biosciences, was co-founded by Harvard professor David Sinclair, a prominent figure in longevity research.
  • Even if this safety trial is successful, proving the drug's efficacy in treating aging-related conditions will require further extensive trials.
  • Significant investment, totaling hundreds of millions of dollars, is flowing into biotechs focused on cellular reprogramming, with some achieving billion-dollar valuations.